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Around 50–60% of adults in western countries are either
overweight or obese with more than 25% falling into the
obese category [1]. The metabolic imbalance underlying obe-
sity has fueled the prevalence of cardiometabolic syndrome—
a constellation of interrelated risk factors ofmetabolic origins
that together promote the increased risk of cardiovascular
disease (CVD) and type II diabetes [2]. These are the major
causes of morbidity, mortality, and sky-rocketing healthcare
costs in industrialized countries. Obesity is the hallmark
component of cardiometabolic syndrome with other key
components being insulin resistance, hypertension, dys-
lipidemia, and endothelial dysfunction. While each of the
associated conditions has an independent effect, their clus-
tering has a synergistic effect, making the risk of developing
cardiovascular disease greater. Obesity with the associated
cardiometabolic syndrome components has a direct effect
on atherogenic dyslipidemia, elevated blood pressure, and
elevated plasma glucose and promotes proinflammatory and
prothrombotic states.
Cardiometabolic syndrome is associated with increased
oxidative stress; however, the source of reactive oxygen
species (ROS) and their exact targets are not well under-
stood. Oxidation products of different organic molecules
including lipids, proteins, and nucleic acids have been used
to demonstrate the presence of oxidative stress in patients
with cardiometabolic syndrome and CVD. Mitochondria
have been shown to be a major source and target of reactive
oxygen species in obesity-induced heart disease with conse-
quences being impaired cardiac energetics, development of
left ventricular hypertrophy, and diastolic dysfunction [3].
Angiotensin II-induced activation of NADPH oxidase also
plays a role, with direct effects via redox posttranslational
modifications of proteins within the caveolar compartment.
The further downstream effects of ROS and redox regulation
are mediated mostly by protein oxidative and nitrosative
posttranslational modifications of proteins [4].
Cardiometabolic syndrome has also been associated with
the presence of a number of inflammatory markers. Low-
grade inflammation is a common manifestation and could
play a role in the pathogenesis of obesity and cardiometabolic
syndrome and its sequelae. Dysregulation of adipose tissue
biology plays a potential role in the initiation of inflammatory
events in obesity and cardiometabolic syndrome causing
chronic inflammatory response characterized by abnormal
adipokine production and the activation of several proin-
flammatory signaling pathways, resulting in the induction of
several proinflammatory cytokines from adipose tissue that
have been suggested to play a role in pathogenesis of CVD.
Furthermore, the dysregulation adipose tissue biology, medi-
ated by increased redox stress and inflammation, adversely
affects angiogenesis both locally and systemically [5], further
contributing to the global impact of cardiometabolic syn-
drome.
It is important to remember that cardiometabolic syn-
drome frequently coexists with many other diseases, linked
by its high prevalence as well as commonalities in aetiology
or even causative contribution. A common nexus between
many of these disease states is the presence of endothelial
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dysfunction, mediated either by decreased synthesis and
enhanced clearance or by impaired bioaction of nitric oxide.
Rheumatoid arthritis, a common autoimmune inflamma-
tory connective tissue condition, has been associated with
increased incidence of CVD. In this issue, T. Dimitroulas
et al. investigated the relationship between levels of sym-
metric dimethylarginine (SDMA), an inactive congener of
asymmetrical dimethylarginine, a marker and mediator of
nitric oxide synthase inhibition, and inflammatory burden
and CVD risk factors in a cohort of rheumatoid disease
patients. Interestingly, the authors have not found such an
association, potentially related to the interacting effects of
antirheumatoid therapy, factors affecting kinetics of SDMA
and potentially methodology for SDMAmeasurement.
Chronic kidney disease is another condition that is
intimately linked with incidence of cardiometabolic syn-
drome and CVD. Kidney disease can result from impaired
cardiovascular function but also can in turn lead toworsening
cardiac and vascular stiffening and fibrosis. A study by S.
Rasˇic´ et al., in this issue, suggests that malondialdehyde
(an oxidative stress marker) and matrix metalloproteinase-9
(a marker/mediator of fibrosis) are significant predictors of
atherosclerosis in chronic kidney disease patients. A. Bakillah
et al. looked at the levels of nitrosatively modified proteins in
plasma of chronic kidney disease patients undergoing kidney
transplantation and found a reduction in nitrated apolipopro-
tein A-I after transplantation, suggesting reduction in oxida-
tive/nitrosative stress. In an animal model of cardiometabolic
syndrome induced in rats by coca cola drinking M. Otero-
Losada et al. found induction of cardiac remodeling and
renal damage, associated with increase in proinflammatory
cytokines, hypertriglyceridemia, and oxidative stress.
While obesity itself has been linked to increased oxidative
stress and inflammation, there are many discrepancies in
various observational studies. In this issue, S. M. Lee et al.
found urinary malondialdehyde and CRP to be positively
associated with visceral fat area in a cohort of moderately
obese middle-aged men. On the other hand, weight loss has
been associated with beneficial cardiometabolic remodeling,
but the exact processes that lead to this improvement in
metabolic and cardiovascular homeostasis are incompletely
understood. S. Karki et al. observed increased expression of
adipose tissue lipolytic genes following bariatric weight loss;
these correlated with improvements in systemic markers of
lipid and glucose metabolism, providing a potential insight
into mechanisms of beneficial effects of weight loss.
Obesity and associated sedentary lifestyle are associated
with an alteration in a number of secreted metabolic modu-
lators; the precise role of many of these is still poorly under-
stood. Irisin is a hormone secreted from the skeletal muscle
under the control of PGC-1𝛼, a metabolic master-regulator.
Irisin has been suggested to be a mediator of the beneficial
effect of exercise, leading to improvement of obesity and glu-
cose homeostasis; however, some controversies regarding its
role remain. M. Quin˜ones et al. found no difference in irisin
levels with induction of obesity or manipulation of leptin lev-
els in 2 rodent models, adding to the uncertainties regarding
the role and regulation of irisin in obesity.
Poor sleep quality has been linked to development of
CVD especially evident in those with disrupted sleep pat-
terns, such as shift workers. T. Kanagasabai and C. I. Ardern
investigated the relationship between sleep quality and para-
meters of oxidative stress and inflammation in a cross-
sectional study. They found some mixed results, in general
suggesting that fair quality sleepers have the most “optimal”
inflammatory and oxidative profile.
Finally, high circulating levels of prothrombotic factors
may play an important role in predisposing to prothrombotic
episodes, which underlie cardiovascular events seen in obe-
sity.This is further compounded by the increased incidence of
atrial fibrillation seen in obese subjects, which in itself confers
a much higher thromboembolic risk. N. Procter et al. studied
the effect of reduction in left atrial deformation, leading to
blood stasis and ultimately thromboembolic events, in atrial
fibrillation. The authors did not find a relationship between
reduced left atrial deformation and measures of thromboem-
bolic risk, inflammatory activation, or platelet reactivity.
This issue on the interplay of cardiometabolic syndrome,
oxidative stress, and inflammation brings together insights
from a wide variety of research and disease fields. These
studies add to the collective body of knowledge regarding
the epidemiology, comorbidities, and mechanistic insights
underlying cardiometabolic syndrome and its cardiovascular
effects. The overall complexity of the pathophysiology of
cardiometabolic syndrome makes these tasks difficult and
overwhelming and further studies frequently addmore ques-
tions than they answer. Developments in redox biomarkers
for human application, currently lagging behind their inflam-
matory counterparts, may assist in dissecting the interaction
of oxidative stress and inflammation in a more personalized
fashion in the clinic and improve targeted therapeutic strate-
gies. Increased understanding of the mechanistic processes
underpinning the development and progression of the car-
diometabolic syndrome will allow us to begin to improve
outcomes from this syndrome which is a major contributor





Doan T. M. Ngo
References
[1] D. M. Thomas, M. Weedermann, B. F. Fuemmeler et al.,
“Dynamic model predicting overweight, obesity, and extreme
obesity prevalence trends,” Obesity, vol. 22, no. 2, pp. 590–597,
2014.
[2] Y.-W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon,
and S. B. Heymsfield, “The metabolic syndrome: prevalence
and associated risk factor findings in the US population from
the Third National Health and Nutrition Examination Survey,
1988–1994,” Archives of Internal Medicine, vol. 163, no. 4, pp.
427–436, 2003.
[3] A. L. Sverdlov, A. Elezaby, F. Qin et al., “Mitochondrial reactive
oxygen species mediate cardiac structural, functional, and
mitochondrial consequences of diet-induced metabolic heart
Mediators of Inflammation 3
disease,” Journal of the American Heart Association, vol. 5,
Article ID e002555, 2016.
[4] H. H. Rasmussen, E. J. Hamilton, C.-C. Liu, and G. A. Figtree,
“Reversible oxidative modification: implications for cardiovas-
cular physiology and pathophysiology,” Trends in Cardiovascu-
lar Medicine, vol. 20, no. 3, pp. 85–90, 2010.
[5] D. T. M. Ngo, M. G. Farb, R. Kikuchi et al., “Antiangio-
genic actions of vascular endothelial growth factor-A165b, an
inhibitory isoform of vascular endothelial growth factor-A, in
human obesity,”Circulation, vol. 130, no. 13, pp. 1072–1080, 2014.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
